Clinical Trial Update: SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II [Phase 2]

View source ↗

Summary

Phase II ORIGIN trial (SAKK 17/18) evaluating first-line gemcitabine with atezolizumab in malignant pleural mesothelioma and non-small cell lung cancer has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED